Syncom Formulations (India) Limited
NSE: SYNCOMF.NS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- National Stock Exchange of India
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ankit Kedarmal Bankda
- Employees
- 998
- Headquarters
- Indore, India
- IPO year
- 2022
- Market cap
- ₹13.8B
- Website
- https://www.syncomformulations.com
Loading SYNCOMF…
Loading profile data…Frequently asked questions about SYNCOMF
What does Syncom Formulations (India) Limited (SYNCOMF.NS) do?
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agent...
Where does SYNCOMF.NS trade?
Syncom Formulations (India) Limited (SYNCOMF.NS) trades on the National Stock Exchange of India.
What sector is SYNCOMF.NS in?
Syncom Formulations (India) Limited (SYNCOMF.NS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Syncom Formulations (India) Limited?
Ankit Kedarmal Bankda is the chief executive officer of Syncom Formulations (India) Limited (SYNCOMF.NS).
Where is Syncom Formulations (India) Limited headquartered?
Syncom Formulations (India) Limited is headquartered in India.
Does SYNCOMF.NS pay a dividend?
Syncom Formulations (India) Limited (SYNCOMF.NS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SYNCOMF.NS go public?
Syncom Formulations (India) Limited (SYNCOMF.NS) completed its initial public offering in 2022.